This is a rare type of breast cancer where the skin of the breast looks red, swollen, and warm, often resembling an infection. It happens when cancer cells spread to the lymph vessels in the breast, causing swelling and redness. It's a serious condition that needs quick medical attention.
Every report comes from a Lived member, sent anonymously.
Have you had Modified Radical Mastectomy for Inflammatory Breast Cancer?
Inflammatory breast cancer (IBC) is a rare, fast-growing type of breast cancer. Instead of forming a distinct lump, the cancer cells block the small lymph vessels in the skin of the breast. Fluid that would normally drain away builds up, so the breast becomes red, swollen and often warm, and the skin can look pitted or dimpled like the peel of an orange (doctors call this peau d'orange). The breast may also feel heavy, tender or burning, grow noticeably larger within a short time, or the nipple may turn inward. The name describes how the breast looks, not the cause: the redness and swelling come from cancer in the skin's lymph vessels, not from an infection. IBC accounts for roughly 1% to 5% of breast cancers in the United States. It matters because it changes over days or weeks, usually has no lump to find, and is already classed as an advanced cancer (stage III or higher) when it is diagnosed. That is why it is treated more intensively than most breast cancers.
The cause of IBC is unknown. Like other breast cancers, it begins with changes in the DNA of breast cells, and most cases are invasive ductal carcinomas, meaning they start in the cells lining the milk ducts and then grow beyond them. A few patterns stand out. IBC tends to be diagnosed at a younger age than other breast cancers, and it is more common, and diagnosed at a younger age, in Black women than in White women. It is also more common in women with obesity than in women at a healthy weight. Otherwise, its risk factors appear to be the same as for breast cancer in general. These are patterns across large groups of people: they do not explain why one person develops IBC, and most people with these risk factors never do.
IBC is diagnosed from a combination of how the breast looks and a biopsy. A clinician examines the breast, asks how quickly the changes appeared, and looks for redness and swelling across a large part of the breast, typically a third or more of its skin. Because the same signs can come from mastitis (a breast infection) or an injury, the history matters: IBC typically appears over weeks and does not improve with antibiotics. On darker skin, the color change can look purple, darkened or bruised rather than pink or red, which is one reason the diagnosis can be missed. Imaging comes next, usually a mammogram and ultrasound, sometimes a breast MRI. IBC often does not show up as a clear mass and can develop between routine screenings, so a normal mammogram does not rule it out. A biopsy confirms the diagnosis: a core needle biopsy of breast tissue, often with a small punch biopsy of the affected skin. The tissue is also tested for hormone receptors (for estrogen and progesterone) and for HER2, a protein that drives cell growth, because these results determine which drugs are likely to work. IBC is often hormone receptor negative. Once cancer is confirmed, scans such as PET/CT or CT check whether it has spread. IBC is stage III when it involves the breast and nearby areas such as the lymph nodes, and stage IV when it has spread to distant parts of the body.
When IBC has not spread to distant organs, the standard plan has three parts given in a set order, often called trimodality therapy. Treatment aims for a cure, and it is more intensive than for most breast cancers because IBC grows quickly and is more likely to return. First comes drug treatment, given before any surgery to shrink the cancer in the breast and lymph nodes and to reach cells that may already have traveled elsewhere. This is usually chemotherapy combined with drugs matched to the biopsy results. For HER2-positive cancer, two antibodies that block HER2, trastuzumab (Herceptin) and pertuzumab, are added. For triple-negative cancer (negative for hormone receptors and HER2), the immunotherapy drug pembrolizumab (Keytruda), which helps the immune system attack cancer cells, may be added and then continued after surgery. When the surgeon removes the breast and no invasive cancer is left, a result called a pathologic complete response, the long-term outlook is considerably better. Second is a modified radical mastectomy: removal of the whole breast, including the affected skin, along with the lymph nodes under the arm. Breast-conserving surgery (lumpectomy) is not recommended, because the cancer runs through the skin's lymph vessels and local control is worse. Breast reconstruction is usually delayed rather than done during the mastectomy, so that it does not hold up radiation. Third is radiation to the chest wall and the surrounding lymph node areas. Afterward, people whose cancer is hormone receptor positive take endocrine (hormone-blocking) therapy, and some continue targeted or other drugs depending on how much cancer was found at surgery. When IBC has already spread at diagnosis, drug treatment is the main tool, and the aim is to control the cancer and its symptoms for as long as possible. Surgery and radiation to the breast are decided case by case: a large trial found that early surgery on the breast did not help people with metastatic breast cancer live longer, although it improved control of the cancer in the breast. Radiation can also ease pain from cancer that has spread to bone. Because IBC is rare and few trials study it specifically, a consultation with a center experienced in IBC and a discussion of clinical trials are worthwhile at any stage.
Treatment for IBC that has not spread is long and demanding because it combines chemotherapy, major surgery and radiation, and people with IBC often receive more treatment for a longer time than people with other breast cancers. Many people need practical help with work, childcare and transport during these months, and a nurse navigator or social worker can help arrange it. Lymphedema, a lasting swelling of the arm caused by damage to its lymph drainage, affects about half of people after standard IBC treatment, because removing the underarm lymph nodes and radiating that area both disrupt drainage. Screening for it early, wearing a fitted compression sleeve and working with a physical therapist make it easier to control. IBC has a less favorable outlook than most breast cancers because it is found at an advanced stage, grows quickly and is more likely to come back. National statistics put five-year relative survival at about 53% when the cancer has spread only to nearby lymph nodes or tissues, and about 22% when it has spread to distant parts of the body. These figures compare people with IBC to the general population, describe people diagnosed years ago, and cannot predict one person's course; the cancer's subtype and how well it responds to the first drug treatment make a large difference. After treatment, regular follow-up watches for recurrence and manages lasting effects. A survivorship plan may include genetic counseling, fertility and family-planning discussions for younger people, physical activity and weight management, and support for body image and the emotional strain of a mastectomy.
See a clinician promptly, rather than waiting for your next screening, if a breast becomes red, swollen, warm or heavy over days to weeks, the skin begins to look pitted like an orange peel, a nipple newly turns inward, or lymph nodes swell under the arm or above the collarbone. A normal recent mammogram is not a reason to wait. If you are being treated for mastitis or a breast infection and the redness and swelling are not clearly better after about a week of antibiotics, contact your care team right away and ask whether IBC has been ruled out. A biopsy and referral to a breast specialist may be needed. During or after treatment, tell your care team about new swelling in the arm or hand on the treated side, or new lumps, nodules or redness on the chest wall or around the scar.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Inflammatory Breast Cancer is like, what's helped you, or ask the community a question.